Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) – study protocol for a pragmatic randomized controlled trial

Julia Carolin Stingl1,2, Katharina Luise Kaumanns1,2*, Katrin Claus1,2, Marie-Louise Lehmann1,2, Kathrin Kastenmüller3, Markus Bleckwenn3, Gunther Hartmann4, Michael Steffens1,2, Dorothee Wirtz1, Ann-Kristin Leuchs1, Norbert Benda1, Florian Meier5, Oliver Schöffski6, Stefan Holdenrieder4, Christoph Coch4 and Klaus Weckbecker3

Abstract

Background: Elderly patients are particularly vulnerable to adverse drug reactions, especially if they are affected by additional risk factors such as multimorbidity, polypharmacy, impaired renal function and intake of drugs with high risk potential. Apart from these clinical parameters, drug safety and efficacy can be influenced by pharmacogenetic factors. Evidence-based recommendations concerning drug-gene-combinations have been issued by international consortia and in drug labels. However, clinical benefit of providing information on individual patient factors in a comprehensive risk assessment aiming to reduce the occurrence and severity of adverse drug reactions is not evident. Purpose of this randomized controlled trial is to compare the effect of a concise individual risk information leaflet with standard information on risk factors for side effects.

Methods/Design: The trial was designed as a prospective, two-arm, randomized, controlled, multicenter, pragmatic study. 960 elderly, multimorbid outpatients in general medicine are included if they take at least one high risk and one other long-term drug (polymedication). As high risk “index drugs” oral anticoagulants and antiplatelets were chosen because of their specific, objectively assessable side effects. Following randomization, test group patients receive an individualized risk assessment leaflet evaluating their personal data concerning bleeding- and thromboembolic-risk-scores, potential drug-drug-interactions, age, renal function and pharmacogenetic factors. Control group patients obtain a standardized leaflet only containing general information on these criteria. Follow-up period is 9 months for each patient. Primary endpoint is the occurrence of a thromboembolic/bleeding event or death. Secondary endpoints are other adverse drug reactions, hospital admissions, specialist referrals and medication changes due to adverse drug reactions, the patients’ adherence to medication regimen as well as health related quality of life, mortality and resulting costs.

(Continued on next page)
Discussion: Despite extensive evidence of risk factors for adverse drug reactions, there are few prospective trial data about an individualized risk assessment including pharmacogenetic information to increase patient safety. By conducting a health economic analysis, we will evaluate if the application of an individualized drug therapy in daily routine is cost-effective.

Trial registration: German Clinical Trials Register: DRKS00006256, date of registration 09/01/15.

Keywords: Individualized medicine, Adverse drug reaction, Elderly, Pharmacogenetics, Polymedication, Drug interaction, ADR risk assessment, Clinical decision support system

Background

Adverse drug reactions (ADR) represent a major public health issue not only due to the morbidity and mortality but also due to the extra costs they cause. About 5–10% of all hospital admissions are estimated to be ADR-associated, 2–6% of them are fatal [1–5]. According to analyses of ADR case reports, approximately 40–60% of all ADR are considered to be preventable [2, 3, 5, 6]. It has been reported that the incidence of ADR increases with age [1, 4–6]. This may be explained by age-related changes in pharmacokinetics, such as increased drug concentrations due to decreased total body water and impaired renal function [7, 8]. Additionally, the prevalence of multimorbidity and polypharmacy is very high in the elderly [9, 10]. In a recent systematic review on ADR in the elderly, these two parameters have been mentioned as significant risk factors for ADR, alongside female sex, impaired renal function, drug-drug-interactions and drugs with narrow therapeutic index, e.g. anticoagulants [11].

Pharmacogenetic factors are known to influence dosing and drug efficacy in patients [12]. For example, clopidogrel effectiveness depends on its transformation into an active metabolite by the genetically variable enzyme cytochrome P 450 2C19 (CYP2C19). Reduced enzyme function has been shown to be significantly associated with decreased platelet inhibition [13–15]. For vitamin K antagonists, cytochrome P 450 2C9 (CYP2C9) is the main drug metabolizing enzyme, and vitamin K epoxide reductase (VKORC1) represents the drugs’ target. They have been shown to significantly influence dosing requirements and anticoagulation stability [16–18]. Evidence-based recommendations for these drugs according to the respective genotypes have been published by the Royal Dutch Pharmacists Association - Pharmacogenetics Working Group [19] and the Clinical Pharmacogenetics Implementation Consortium (CPIC) [20]. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have included pharmacogenetic information for clopidogrel in the drug labels, the FDA also for the vitamin K antagonist warfarin [21, 22].

Another measure to increase patient safety is the use of computerized clinical decision support systems. They have been shown to be a cost-effective possibility to reduce preventable ADR and medication errors in inpatient and ambulatory care [23–26]. Furthermore, some randomized controlled trials investigating the effect of a comprehensive medication review in elderly populations have suggested a reduction of medication-related hospital admissions, but the studies were underpowered and the results were not statistically significant [27, 28]. Therefore, a randomized controlled trial with a large cohort of patients at particularly high risk for ADR is needed for further investigation.

The aim of this study is to test if individualization of drug therapy based on the most important categories of relevant known ADR risk factors may improve safety and individual efficacy of drug therapy if the doctor and the patient are getting this information in a timely and easy-to-understand format. We focus our study on a collective of elderly, multimorbid, polypattern ADR-high risk patients. As antithrombotics range among the most frequently ADR-associated drugs leading to hospitalizations in the elderly [29, 30] and have high potential for particularly severe ADR [31, 32], these drugs were determined as index medication for the study.

Methods/Design

Study aim
The aim of the study is to evaluate the effect of an individualized comprehensive risk assessment and information leaflet regarding medication compared to a standardized one on adverse drug reactions in an elderly high-risk population.

Design
The IDrug-study is a prospective, multicenter, two-arm, randomized, controlled, pragmatic trial. Eligible patients are randomized to either test or control group. Control group patients receive a standardized information leaflet about risk factors for ADR. An individualized leaflet containing the same general information plus an additional individualized risk assessment is handed out to test group patients. In the following passages, the study design will be described in detail.
Study endpoints
Primary endpoint is the occurrence of a thromboembolic or bleeding event or death within a 9 months study period. Secondary endpoints are the occurrence of other ADR, the number of hospital admissions due to ADR, the number of specialist referrals due to ADR, the number of medication changes, the patients’ adherence to the medication regimen, time to death, health-related quality of life, costs of medication and of additional general practitioner (GP) consultations and hospital treatments as well as a cost-benefit analysis.

Inclusion and exclusion criteria
Patients are eligible if they are at least 60 years old, have more than one chronic disease and take two or more prescription drugs. They have to be on long-term treatment with oral anticoagulants (phenprocoumon, warfarin, dabigatran, apixaban, rivaroxaban) or antiplatelets (clopidogrel, prasugrel, ticagrelor, ticlopidin) as high risk index medication. Furthermore, they must be physically and mentally able to give written consent to participate in the study. Patients will be excluded if they are unable to give consent or unable to fill in the required questionnaires (SF-36 for health-related quality of life [33], Morisky score for adherence to medication regimen [34] and social state).

Sample size
Sample size calculation was based on the primary endpoint and its primary analysis. Preceding studies reported incidence rates ranging from 8 to 10.6 % for thromboembolic and bleeding events in a population of elderly polymedicated patients on oral anticoagulants [32, 35]. Thus, for sample size calculation, we assumed an incidence rate of 10 % in the control group, which we assumed to be reduced by half as a result of the individualized risk assessment (i.e. to 5 %). To detect this anticipated difference with a power of 80 % using the Cochran-Mantel-Haenszel test (assuming equal effects in all strata), a sample size of 435 patients per arm is required. Assuming a dropout rate of 10 % about 960 patients need to be included in the study.

Recruitment
The study is conducted in the area of Bonn, Cologne and the Rhine-Sieg-district, Germany. 40–80 GP-practices situated in this area participate in the study. After being instructed by the Institute of General Practice and Family Medicine Bonn, the general practitioners create a list of eligible patients. They name the number of patients to the institute and in return obtain in a first step a random selection of 10 patients to be asked by the GP to participate in the study. This random selection is performed using prefabricated lists provided by the Department of Biostatistics of the Federal Institute for Drugs and Medical Devices Bonn to avoid selection bias. Overall each GP-practice is planned to enroll 12–24 patients. The workflow of the IDrug study is illustrated in Fig. 1.

Patient information and inclusion
Written informed consent is obtained by the general practitioner. After enrollment, a blood sample is taken and sent to the accredited Institute of Clinical Chemistry and Clinical Pharmacology of the University of Bonn for genotyping (CYP2C9, CYP2C19 and VKORC1). The patient’s medical history is documented on paper-based Case Report Forms (CRF). The collected data include the patient’s demographic data, such as age, gender, weight, height, blood test results (creatinine, thrombocytes, hemoglobin and liver enzymes), alcohol consumption, smoking state, anticoagulation/antiplatelet therapy regimen, medication and diagnoses. Additionally, the HAS-BLED-Score [36] for bleeding risk (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile internationalized normalized ratio, elderly (>65 years), drugs/food concomitantly) and the CHA2DS2-VASc-Score [37] for thromboembolic risk (congestive heart failure, hypertension, age, diabetes, stroke, vascular disease, age, sex category) are recorded. Once completely filled in, the CRF is faxed to the Federal Institute for Drugs and Medical Devices Bonn for randomization and risk assessment.

Randomization
Randomization is performed upon receipt of the CRF and is stratified by GP-practice and gender to account for potential influence of GP and gender and to ensure balanced groups within each stratum. Randomization lists are provided by the Biostatistics Unit of the Federal Institute for Drugs and Medical Devices Bonn. According to the allocated study-arm, either a standardized or an individualized risk assessment leaflet is written and sent out to the GP in duplicate, as one copy will be handed out to the patient.

Risk assessment
Both risk assessment leaflets contain general information on risk factors for adverse drug reactions. However, the individualized leaflet also includes an additional personalized risk evaluation which takes the patients clinical data into account. For test group patients, their individual HAS-BLED- and CHA2DS2-VASc-Scores are calculated. The current medication is checked for potential drug-drug-interactions and it is checked whether dose adjustments related to the patients’ kidney function would apply, using two independent validated evidence-based clinical decision support systems, AiDKlinik® [38].
and the ABDA database [39]. Furthermore, the patients' genetic profiles for CYP2C9, CYP2C19 and VKORC1 are matched with their medication to check for potential drug-gene-interactions according to their genotypes. References are the guidelines published by the Royal Dutch Pharmacists Association - Pharmacogenetics Working Group [19] and the Clinical Pharmacogenetics Implementation Consortium (CPIC) [20]. The standardized leaflet, however, only contains general information about these risk factors for adverse drug reactions.

The leaflets have a short and clearly arranged design in order to be implementable in everyday practice. They only contain clinically relevant information. Additionally, they are written in a generally understandable manner,
so that they can be read easily by doctors as well as patients. A scheme of the risk assessment leaflets is displayed in Fig. 2.

**Follow-up and blinding**

Follow-up time is 9 months for each patient. Overall, 4 visits are scheduled at intervals of 3 months. The study starts at visit 1 when the patient receives the risk assessment leaflet. During this visit, the general practitioner hands out the leaflet and explains its contents to the patient. It is at the discretion of the GP in which way and to what extent he uses the provided information for further treatment, no specifications are made. Patients are considered to be blinded to group assignment, since group assignment is not actively communicated at any time and both risk assessment leaflets have a very similar layout.

During each visit, the following information is documented in the CRF: reason for GP-consultation, vital signs, ECOG score for the patient’s physical condition [40], adverse events (bleeding events, thromboembolic events and others), number of GP-consultations in the meantime, specialist referrals, hospital admissions, sick leaves, remedies and aids and other procedures (e.g. emergency department visits, rehabilitation etc.). Data about anticoagulation/antiplatelet therapy regimen, medication and diagnoses are updated during each visit. Additionally, patients are asked to fill in questionnaires about their health related quality of life (SF-36 [33], filled in at each visit), their adherence to the medication regimen [34] (filled in at the beginning and end of the study) and their social state (filled in once at the beginning of the study).

**Data management and monitoring**

The patients’ data is documented on paper-based Case Report Forms by the general practitioners, the practice...
staff and staff of the Institute of General Practice and Family Medicine Bonn. It is transferred to a GCP conform electronic database by the data management of the Federal Institute for Drugs and Medical Devices Bonn. To guarantee data quality, double data entry is performed. Queries are documented in an electronic database and processed during monitoring visits. For each practice, three of these visits are scheduled. The first one takes place after inclusion of 1 to 3 patients, the second one after inclusion of 10 to 15 patients and the third one when the practice finishes the study. Furthermore, practices are monitored via telephone and additional interim visits regularly. Monitoring is performed by the Study Center of the Institute of Clinical Chemistry and Clinical Pharmacology, University of Bonn.

**Dropout criteria**

Study participation is terminated if the patient withdraws consent or if continuous data collection cannot be guaranteed (e. g. if the patient changes the GP or is absent for a long time). Discontinuation of anticoagulant/antiplatelet therapy after start of the study and receipt of the risk assessment leaflet (visit 1) does not lead to exclusion.

**Ethic approval, data protection and funding**

The IDrug study has been approved by the Ethics Committees of the University of Bonn, of the Medical Association of North Rhine and of the Medical Association of Rhineland-Palatinate. It is performed according to the study protocol, ICH-GCP criteria, EU directives and applicable legal requirements. According to the Declaration of Helsinki, written consent is obtained after oral and written information. Person-identifying data, such as names and birthdays, remain at the GP-practices at all times. All data will be stored for 10 years. Patient information is pseudonymized before transfer to the Federal Institute for Drugs and Medical Devices or the Institute of Clinical Chemistry and Clinical Pharmacology. The IDrug study is financially supported by the Federal Ministry of Education and Research (BMBF). The protocol has been peer-reviewed in a strictly competitive process with several external reviewers from non-German countries evaluating the grant applications.

**Statistical analysis**

**Primary endpoint**

The proportion of patients with an event (i. e. thromboembolic or bleeding event or death) will be compared between the two study arms using the Cochran-Mantel-Haenszel-Test stratified by gender and medical practice. Following the intention-to-treat principle, all randomized patients will be analyzed according to their randomized allocation. Dropouts will be counted as treatment failure in primary analysis. Risk reduction is estimated by the Mantel-Haenszel estimator of the common relative risk with the corresponding 95% confidence interval. Additional sensitivity analyses will be performed, which include evaluation of different covariate structures.

**Secondary endpoints**

The SF-36-questionnaire for health related quality of life will be analyzed with a mixed model for repeated measurements using an unstructured covariance matrix. The mixed model contains the categorical covariates treatment, visit, gender and medical practice, a continuous covariate for the baseline SF-36-score and a treatment by visit interaction. Evaluation of drug-associated morbidity involves descriptive analysis of the number of patients with severe adverse drug reactions, the number of hospital admissions and specialist referrals due to ADR and the number of medication changes during the study period. The adherence scale will be evaluated using the non-parametric Wilcoxon-test. Survival time will be analyzed using a log-rank-test stratified by gender and medical practice. Additionally, a Cox-regression, which includes covariates treatment, gender, medical practice, age group and anticoagulant as well as a treatment by gender interaction, will be performed as a sensitivity analysis. The direct costs of the prescribed medication, unexpected GP-visits and hospitalizations will be collected and used for a cost-effectiveness analysis to compare the two study groups. In this context, two types of health outcomes will be examined. Firstly, the incidence of adverse events and secondly, the quality-adjusted-life-years (QALY) measures using the SF-36-questionnaire.

**Discussion**

Objective of the IDrug study is to further investigate individual patient ADR risk factors in a randomized controlled fashion in a real-world clinical setting with elderly patients at high risk for ADR. In contrast to preceding clinical studies, clinical and pharmacogenetic risk factors are not considered in isolation, but together resulting in a comprehensive medication review in form of a risk assessment leaflet. The pragmatic study design does not only allow to obtain valuable data with high external validity, but also paves the way for clinical applicability. For the purpose of realistic conditions, GP-practices were chosen as study sites. Due to the inclusion criteria a broad representative patient population can be acquired. The high risk characteristic of the study cohort might enhance detection rates of adverse drug reactions.

One limitation of the study is that the degree of accuracy of blinding might decrease over the study period, as
each GP will receive both versions of risk assessment leaflets and, therefore, might be able to identify study groups during the course of the trial. In contrast, patients only get to see their own risk assessment leaflets. Therefore, it is less likely that blinding is broken for patients. Furthermore, although the provided risk assessment covers the most important risk factors for ADR, some parameters are not included, e.g. drug-disease interactions and missing drug indications. The reason is to keep the leaflets as short as possible to ensure the GP's and patient's motivation to read it.

To our knowledge, IDrug is the first randomized controlled trial evaluating the impact of a comprehensive individualized risk assessment including genotyping on adverse drug reactions in a large elderly high risk population. Based on the study results, we will evaluate whether this individualized approach has the potential to increase patient safety in daily routine by reducing ADR in a cost-effective way. This may advance development of rational, evidence-based policies for the application of pharmacogenetic testing in individualized drug therapy in clinical practice.

Abbreviations
ADR: Adverse drug reaction(s); CHA2DS2-VASc: Congestive heart failure, hypertension, age, diabetes, stroke, vascular disease, age, sex category; CRF: Case report form(s); CYP: Cytochrome P450 enzyme; DNA: Deoxyribonucleic acid; ECOG: Eastern cooperative oncology group; EMA: European Medicines Agency; EU: European Union; FDA: U.S. Food and Drug Administration; GCP: Good clinical practice; GP: General practitioner; HAS-BLED: Hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly (>65 years), drugs/alcohol concomitantly; ICH: International conference of harmonization; INR: International normalized ratio; QALY: Quality-adjusted life-years; SF: Short form; VKORC: Vitamin K epoxide reductase complex.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
JCS is the principal investigator and designed the study. KLK, KC and M-LL performed study coordination and prepared the risk assessment leaflets. KW, MB and KK organized GP recruitment and supervised the practices. GH and SH performed study coordination and prepared the risk assessment leaflets. NB, JCS is the principal investigator and designed the study. KLK, KC and M-LL planned and carried out genetic analyses. CC arranged study monitoring. NB, MB and KK organized GP recruitment and supervised the practices. GH and SH performed study coordination and prepared the risk assessment leaflets. DW and AL planned sample size estimation, randomization and biometrical analysis. JCS planned sample size estimation, randomization and biometrical analysis. JCS is the principal investigator and designed the study. AL, DW and KLK monitored the study and carried out the analysis. ACR, TARM, JCS and KLK interpreted the data. DW and KLK drafted the manuscript. JCS designed the study and supervised the study. All authors read and approved the final manuscript.

Acknowledgements
We thank all the general practitioners and their staff who participate in the study, Miriam Böhme, Karin Holz and Magdalena Padur for data management as well as Marion Zerlett, Yvonne Borck and Uta Wolber for monitoring. Many thanks to Prof. Walter Haeffeli from the University of Heidelberg who provided the ADKlinik® clinical decision support system. The IDrug study is financially supported by the Federal Ministry of Education and Research (BMBF).

Author details
1Research Division, Federal Institute for Drugs and Medical Devices, Kurt-Georg-Kiesinger-Allee 3, 53175 Bonn, Germany. 2Centre for Translational Medicine, University of Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany. 3Institute of General Practice and Family Medicine, University of Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany. 4Institute of Clinical Chemistry and Clinical Pharmacology, University of Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany. 5Department of Economics and Management, Wilhelm Löhe University of Applied Sciences, Merkurstraße 41, 90763 Fürth, Germany. 6Department of Health Management, University of Erlangen-Nürnberg, Lange Gasse 20, 90403 Nürnberg, Germany.

Received: 29 March 2016 Accepted: 14 April 2016

Publicly funded: 26 April 2016

References
1. Meier F, Maas R, Sonst A, Patapova A, Muller F, Plank-Kiegele B, Pfreiffer B, Schoffski O, Buike T, Dormann H. Adverse drug events in patients admitted to an emergency department: an analysis of direct costs. Pharmacoeconomic Drug Saf. 2015;24(21):176–86.
2. Leendertse AJ, Egberts AC, Stoker LJ, van den Berst PM, Group HS. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med. 2008;168(17):1890–6.
3. Pirnhammed M, James S, Meakins S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckinridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004;329(7456):15–9.
4. Schneeweiss S, Hasford J, Gottler M, Hoffmann A, Riethling AK, Avorn J. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol. 2002;58(4):285–91.
5. van der Hooft CS, Dielemans JP, Siemes C, Aarnoudse AJ, Verhamme KM, Stricker BH, Strukkenboom MC. Adverse drug reaction-related hospitalisations: a population-based cohort study. Pharmacoeconomic Drug Saf. 2008;17(4):365–71.
6. Benard-Laribiere A, Miremont-Salame G, Perault-Pochat MC, Noize P, Hamburum F, Centre ESquitobioFno. Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study. Fundam Clin Pharmacol. 2015;29(1):106–11.
7. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.
8. Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab. 2011;12(7):601–10.
9. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65.
10. Violan C, Fougere-Boreu Q, Flores-Mateo G, Salisbury C, Blom J, Freitag M, Glynn L, Muth C, Valderas JM. Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. PLoS One. 2014;9(7):e102149.
11. Alhawasi TT, Kras I, Bajorek BV, Pont LG. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clin Interv Aging. 2014;9:6079–86.
12. Stingl JC, Just KS, Kaumanns K, Schurg-Urbanik M, Scholl C, von Mallek D, Brockmoller J. [Personalized drug therapy based on genetics: Possibilities and examples from clinical practice]. Der Intern. 2016;57(3):289–97.
13. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Alach M, Lechat P, Gaussem P. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108(2):2244–7.
14. Giusti B, Gori AM, Marcucci R, Saracini C, Sestini J, Panica R, Valente S, Antonucci D, Abbate R, Gensini GF. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 V1501 +12G/A and P2Y12 774AC polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics. 2007;17(12):1057–64.
15. Mega JL, Close SL, Wiviott SD, Braunwald E, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354–62.
16. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, Jaillon P, Beaune P, Laurent-Puig P, Becqueumont L, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005;106(1):135–40.
18. International Warfarin Pharmacogenetic C, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753–64.

19. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ, et al. Pharmacogenetics: from bench to byte—an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662–73.

20. Scott SA, Sangkulth K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shulkind AR, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy. 2013 update. Clin Pharmacol Ther. 2013;94(3):317–23.

21. U. S. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm (2015). Accessed 24 Feb 2016.

22. Ebrmann F, Caneva L, Prasad K, Paulmichl M, Malepaard M, Llerena A, Ingelman-Sundberg M, Papaluca-Amati M. Pharmacogenomic information in drug labels: European Medicines Agency perspective. Pharmacogenomics J. 2015;15(3):201–10.

23. Forrester SH, Hepp Z, Roth JA, Wintz HS, Devine EB. Cost-effectiveness of a computerized provider order entry system in improving medication safety ambulatory care. Value Health. 2014;17(4):340–9.

24. Nuckols TK, Asch SM, Patel V, Keeler E, Anderson L, Buntin MB, Escarce JJ. Implementing computerized provider order entry in acute care hospitals in the United States could generate substantial savings to society. Jt Comm J Qual Patient Saf. 2015;41(8):341–50.

25. Radley DC, Wasserman MR, Olsho LE, Shoemaker SJ, Spranca MD, Bradshaw B. Reduction in medication errors in hospitals due to adoption of computerized provider order entry systems. J Am Med Inform Assoc. 2013;20(3):470–6.

26. Vermeulen KM, van Doornmaal JE, Zaal RJ, Mol PG, Lendelink AW, Haaijer-Ruskamp FM, Kostenberg JS, van den Berl PM. Cost-effectiveness of an electronic medication ordering system (CPOE/CDSS) in hospitalized patients. Int J Med Inform. 2014;83(8):572–80.

27. Gillespie U, Alassaad A, Henrohn D, Garho M, Hammarlund-Udenaes M, Toss H, Kettis-Lindblad A, Melhus H, Morlin C. A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older: a randomized controlled trial. Arch Intern Med. 2009;169(9):894–900.

28. Leendertse AJ, de Koning GH, Goudswaard AN, Belitser SV, Verhoef M, de Gier H, Egberts AC, van den Berl PM. Preventing hospital admissions by reviewing medication (PHARM) in primary care: an open controlled study in an elderly population. J Clin Pharm Ther. 2013;38(5):379–87.

29. Budnitz DS, Sheth N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med. 2007;147(11):755–65.

30. Franceschi M, Scarcelli C, Nino V, Seripa D, Pazienza AM, Pepe G, Colusso AM, Pacilli L, Pilotto A. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients. Drug Saf. 2008;31(6):545–56.

31. Schneeweiss S, Gagne JJ, Henault LE, Regan S. Major hemorrhage using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.

32. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.

33. Schneeweiss S, Gagne JJ, Henault LE, Regan S. Major hemorrhage using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.

34. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74.

35. Pernod G, Labarere J, Yver J, Safier B, Berremili T, Fontaine M, Franco G, Bosson JL. EDUCAWK: reduction of oral anticoagulant-related adverse events after patient education: a prospective multicenter open randomized study. J Gen Intern Med. 2008;23(9):1441–6.

36. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100.

37. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.